497 related articles for article (PubMed ID: 37062012)
1. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson's disease.
Riederer P; Nagatsu T; Youdim MBH; Wulf M; Dijkstra JM; Sian-Huelsmann J
J Neural Transm (Vienna); 2023 May; 130(5):627-646. PubMed ID: 37062012
[TBL] [Abstract][Full Text] [Related]
2. Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson's disease.
Riederer P; Monoranu C; Strobel S; Iordache T; Sian-Hülsmann J
J Neural Transm (Vienna); 2021 Oct; 128(10):1577-1598. PubMed ID: 34636961
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein in Parkinson's disease: causal or bystander?
Riederer P; Berg D; Casadei N; Cheng F; Classen J; Dresel C; Jost W; Krüger R; Müller T; Reichmann H; Rieß O; Storch A; Strobel S; van Eimeren T; Völker HU; Winkler J; Winklhofer KF; Wüllner U; Zunke F; Monoranu CM
J Neural Transm (Vienna); 2019 Jul; 126(7):815-840. PubMed ID: 31240402
[TBL] [Abstract][Full Text] [Related]
4. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S; Chan P
Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
[TBL] [Abstract][Full Text] [Related]
5. Toxic Feedback Loop Involving Iron, Reactive Oxygen Species, α-Synuclein and Neuromelanin in Parkinson's Disease and Intervention with Turmeric.
Jansen van Rensburg Z; Abrahams S; Bardien S; Kenyon C
Mol Neurobiol; 2021 Nov; 58(11):5920-5936. PubMed ID: 34426907
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein aggregation and transmission in Parkinson's disease: a link to mitochondria and lysosome.
Wang R; Sun H; Ren H; Wang G
Sci China Life Sci; 2020 Dec; 63(12):1850-1859. PubMed ID: 32681494
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of α-Synuclein in Parkinson's Disease: From a Neuron-Glia Crosstalk Perspective.
Yi S; Wang L; Wang H; Ho MS; Zhang S
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499080
[TBL] [Abstract][Full Text] [Related]
8. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element.
Olivares D; Huang X; Branden L; Greig NH; Rogers JT
Int J Mol Sci; 2009 Mar; 10(3):1226-60. PubMed ID: 19399246
[TBL] [Abstract][Full Text] [Related]
9. Lewy Bodies: A Spectator or Salient Killer?
Sian-Hulsmann J; Monoranu C; Strobel S; Riederer P
CNS Neurol Disord Drug Targets; 2015; 14(7):947-55. PubMed ID: 25801839
[TBL] [Abstract][Full Text] [Related]
10. The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease.
Li HY; Liu DS; Zhang YB; Rong H; Zhang XJ
Biophys Chem; 2023 Dec; 303():107122. PubMed ID: 37839353
[TBL] [Abstract][Full Text] [Related]
11. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
14. The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease.
Wan OW; Chung KK
PLoS One; 2012; 7(6):e38545. PubMed ID: 22701661
[TBL] [Abstract][Full Text] [Related]
15. Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation.
Oh Y
BMB Rep; 2019 Jun; 52(6):349-359. PubMed ID: 31186086
[TBL] [Abstract][Full Text] [Related]
16. The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson's disease.
Sian-Hulsmann J; Riederer P
J Neural Transm (Vienna); 2020 May; 127(5):749-754. PubMed ID: 32318880
[TBL] [Abstract][Full Text] [Related]
17. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity.
Stoll AC; Sortwell CE
Neurobiol Dis; 2022 Sep; 171():105804. PubMed ID: 35764290
[TBL] [Abstract][Full Text] [Related]
18. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
19. Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
Kuznetsov IA; Kuznetsov AV
Math Biosci; 2022 Feb; 344():108754. PubMed ID: 34890628
[TBL] [Abstract][Full Text] [Related]
20. Alpha-Synuclein in Alcohol Use Disorder, Connections with Parkinson's Disease and Potential Therapeutic Role of 5' Untranslated Region-Directed Small Molecules.
Cahill CM; Aleyadeh R; Gao J; Wang C; Rogers JT
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33096655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
